Syndax Pharmaceuticals (SNDX) Current Deferred Revenue (2015 - 2021)

Syndax Pharmaceuticals' Current Deferred Revenue history runs 7 years deep, the most recent figure standing at $12.4 million for Q3 2021.

• In Q3 2021, Current Deferred Revenue rose 717.4% year-over-year to $12.4 million; the TTM figure through Sep 2021 stood at $12.4 million (up 717.4% YoY), while the FY2020 annual figure was $1.5 million, changed 0.0% from the prior year.
• Current Deferred Revenue was $12.4 million for Q3 2021 at Syndax Pharmaceuticals, up from $1.5 million in the prior quarter.
• In the past five years, Current Deferred Revenue ranged from a high of $12.4 million in Q3 2021 to a low of $1.2 million in Q1 2017.
• Historically, Current Deferred Revenue has averaged $2.0 million across 5 years, with a median of $1.5 million in 2018.
• The sharpest annual moves came in 2018 and 2021: Current Deferred Revenue decreased 3.56% in 2018, then jumped 717.4% in 2021.
• A 5-year view of Current Deferred Revenue shows it stood at $1.6 million in 2017, then retreated by 3.56% to $1.5 million in 2018, then changed by 0.0% to $1.5 million in 2019, then changed by 0.0% to $1.5 million in 2020, then surged by 717.4% to $12.4 million in 2021.
• The last three Current Deferred Revenue figures came in at $12.4 million (Q3 2021), $1.5 million (Q2 2021), and $1.5 million (Q1 2021), per Business Quant data.